PFx Biotech Secures €2.5M Seed Round to Revolutionize Nutrition with Bioactive Human Milk Proteins

PFx Biotech, Lda is thrilled to announce a significant funding milestone, having successfully raised €2,500,000 to further accelerate its groundbreaking mission in the biotech arena. Founded in 2022 and proudly based in UPTEC, Porto, PFx Biotech is at the forefront of a revolution in nutrition and health, leveraging the unique advantages of precision fermentation to produce alternative human milk proteins. Recognizing human milk proteins as the gold standard in early life nutrition, the company is committed to harnessing these bioactive molecules to develop ingredients that not only promote robust immune function but also offer unparalleled nutritional benefits across various age groups. With this fresh injection of capital, PFx Biotech plans to expand its research and development capabilities, refine its production processes, and increase its market outreach. The funding will also support critical scale-up initiatives, enabling the production of non-allergenic, GMO-, dairy- and animal-free proteins that are easily digestible and highly bioavailable—making them ideal for a diverse range of consumers including infants, the elderly, and athletes. Backed by a team with deep expertise in dairy proteins, fermentation, molecular biology, and sustainable innovation, PFx Biotech is poised to disrupt traditional protein production systems. The company’s innovative approach not only addresses urgent nutritional challenges but also champions environmental and social responsibility by offering eco-friendly alternatives to conventional protein sources. This successful funding round marks an exciting new chapter for PFx Biotech, reinforcing its commitment to creating healthier lives and a better planet, and setting the stage for meaningful advancements in the future of nutrition and public health.